What are the top neurotech startups by total funding raised?

Is Neuralink still the most-funded neurotech startup?

Neuralink is currently the best-funded neurotech startup we identified, with approximately $1.33 billion raised, putting it more than $500 million ahead of its closest competitor in our ranking.

Neuralink's $650 million Series E, announced in June 2025, accounts for almost half its cumulative funding. The round attracted ARK Invest, Founders Fund, Sequoia Capital, Lightspeed Venture Partners and other investors. Combined with its $280 million Series D in 2023, those two rounds brought in $930 million, roughly 70% of all the capital Neuralink has raised.

The company is now in a different funding category from most brain-computer interface developers. Precision Neuroscience has raised $430 million, Synchron $345 million, and Science Corporation approximately $490 million, according to the latter company's legal adviser, Cooley. Neuralink has attracted roughly three times as much capital as these major competitors.

Its lead becomes less overwhelming when we include companies developing other neurological technologies. Insightec, which uses focused ultrasound to treat movement disorders, has raised approximately $800 million. Saluda Medical, which develops electrical stimulation for chronic pain, has accumulated hundreds of millions in historical financing.

Neuralink still leads on reported cumulative funding, but the size of that lead depends on how broadly we define neurotechnology.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Which neurotech companies have raised the most money?

Neuralink, Insightec, Saluda Medical, Science Corporation and Precision Neuroscience currently occupy the top five positions in our selected neurotechnology funding comparison.

We include companies developing technology that records, stimulates, interfaces with or directly treats the nervous system. That covers brain implants, spinal cord stimulation, focused ultrasound, neural prosthetics and non-invasive brain stimulation. Conventional pharmaceutical companies and general digital health startups fall outside this comparison.

We reviewed company announcements, funding databases and financial disclosures. The figures are approximate, expressed in US dollars, and represent reported historical financing rather than current cash reserves. Some database totals include debt or other instruments alongside equity.

Rank	Neurotech company	Total funding reported	Main technology
1	Neuralink	$1.33B	Implantable brain-computer interfaces
2	Insightec	~$797M–$811M	MRI-guided focused ultrasound
3	Saluda Medical	~$644M	Closed-loop spinal cord stimulation
4	Science Corporation	~$490M–$520M	Visual prosthetics and neural interfaces
5	Precision Neuroscience	$430M	High-density cortical interfaces
6	Synchron	$345M	Endovascular brain-computer interfaces
7	BrainCo	~$336M	Non-invasive BCI and assistive devices
8	Cala Health	~$307M	Peripheral nerve stimulation
9	Merge Labs	$252M	Non-invasive brain-computer interfaces
10	Cognito Therapeutics	~$233M	Light-and-sound neural stimulation

One correction to older funding datasets is particularly important. Science Corporation's legal adviser, Cooley, reported approximately $490 million raised after its March 2026 Series C, while CB Insights lists $520 million. That places Science above Precision Neuroscience, contrary to rankings still using older Science funding figures.

Saluda Medical is also a historical comparison rather than a current private startup, having listed on the Australian Securities Exchange in December 2025. Insightec's total includes debt financing. The ranking is therefore best understood as a comparison of major neurotechnology companies by reported historical capital raised, rather than a definitive equity-only ranking of private startups.

Why has Neuralink raised so much more money than other brain-computer interface startups?

Neuralink's funding advantage comes from unusually large venture rounds and an ambitious technology platform that combines brain implants, surgical robotics, custom electronics and artificial intelligence.

The difference in individual rounds is striking. Neuralink's $650 million Series E was 2.6 times Precision Neuroscience's $250 million Series D, nearly 2.8 times Science Corporation's $230 million Series C, and 3.25 times Synchron's $200 million Series D.

Neuralink is developing its N1 implant and R1 surgical robot to record brain activity and translate neural signals into digital commands. Its clinical work initially focuses on people with severe paralysis, but the company has also discussed applications involving vision restoration, speech and broader brain-computer communication.

This wider ambition helps explain its appeal to investors. Neuralink is attempting to build technology that could eventually serve several neurological conditions and, potentially, applications beyond medicine.

Its approximately $9 billion valuation associated with the 2025 financing also shows how much investors are willing to pay for that possibility. The valuation is several times its cumulative funding and rests heavily on expectations about future success, rather than demonstrated profitability. Investors are paying a considerable premium for what Neuralink might become.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Is Insightec really the second-most-funded neurotech company?

Insightec is one of the most heavily financed neurological technology companies, with approximately $797 million to $811 million in reported historical funding, although a substantial portion came from debt.

Founded in 1999, Insightec develops the Exablate Neuro platform, which uses MRI-guided focused ultrasound to treat neurological conditions without conventional brain surgery. Its technology is used for disorders including essential tremor and certain Parkinson's disease symptoms.

The company raised $150 million in equity financing in June 2024, led by Fidelity Management & Research Company and co-led by Nexus Neurotech Ventures and Ally Bridge Group. Funding databases also record a $200 million debt financing in 2022.

That debt component is important. If we subtract the identified $200 million debt transaction from the approximately $800 million reported total, we get around $600 million. This remains a substantial amount, although it is only an illustrative adjustment rather than a verified equity-only total.

Insightec also serves a different market from Neuralink. Its technology delivers therapeutic ultrasound, while Neuralink records brain signals to enable communication and control. Both belong to neurotechnology, but comparing their funding is more useful for understanding investor capital across neurological devices than for identifying the leading brain-computer interface startup.

Why is Saluda Medical near the top despite no longer being a startup?

Saluda Medical remains one of the best-funded companies in neurotechnology, with approximately $644 million in historical financing reported by Dealroom, but it became publicly listed in December 2025.

Saluda develops the Evoke spinal cord stimulation system for chronic pain. Evoke measures neural responses and automatically adjusts electrical stimulation, allowing treatment to respond to changes in the patient's nervous system.

Its commercial results make it especially interesting. According to Saluda's July 2026 Australian Securities Exchange disclosure, the company generated $90.2 million in revenue during the financial year ended June 2026, up 28% from the previous year. Fourth-quarter revenue reached $27 million, growing 43% year over year.

Saluda also reported 45% US revenue growth and 50% growth in US implanted patients during that quarter. These figures show an established medical-device business selling products, training physicians and increasing implant volumes.

The company raised approximately A$230.8 million, equivalent to about US$150 million, through its December 2025 IPO. We would exclude Saluda from a strict ranking of currently private startups, while retaining it in a broader comparison of neurotech companies that have attracted substantial funding.

Has Science Corporation overtaken Precision Neuroscience in total funding?

Science Corporation currently appears to have raised more capital than Precision Neuroscience, with approximately $490 million to $520 million reported versus Precision's $430 million.

Science Corporation announced a $230 million Series C in March 2026. Cooley, the law firm that advised the company, said the transaction brought its cumulative funding to approximately $490 million. CB Insights reports $520 million across six financing events, highlighting a difference between database coverage and the total stated alongside the financing.

Founded in 2021 by former Neuralink president Max Hodak, Science is developing technologies to restore sensory functions. Its main near-term product, PRIMA, combines a small retinal implant with camera-equipped glasses to help people with severe visual impairment.

Precision Neuroscience, meanwhile, raised $250 million in September 2026, bringing its cumulative funding to $430 million. It develops a thin electrode array placed on the brain's surface to record neural activity.

The two companies have raised similar amounts through different strategies. Science is concentrating heavily on visual restoration and bringing PRIMA toward market, while Precision is building a cortical interface platform for recording and stimulation.

Science's financing lead over Precision is approximately $60 million using Cooley's figure, or $90 million using CB Insights. Either way, Science currently ranks higher on reported capital raised.

Is Precision Neuroscience catching up with Neuralink?

Precision Neuroscience has made a major jump in funding, but Neuralink still has roughly three times its cumulative capital.

Precision announced a $250 million Series D in September 2026, increasing its total funding from approximately $180 million to $430 million. One financing round therefore increased its cumulative total by about 139%.

The round was co-led by Pershing Square, the Ackman Oxman Institute and an undisclosed life sciences investment fund. Participants included ARK Invest, B Capital, Mubadala Capital and other institutional investors.

Precision has also reported more than 100 patient procedures across 18 medical institutions. Its Layer 7 Cortical Interface received FDA 510(k) clearance in March 2025 for temporary recording, monitoring and stimulation of brain activity for up to 30 days.

These are meaningful clinical and regulatory milestones. Precision has demonstrated that its technology can be used in medical procedures across multiple institutions, although temporary-use clearance does not establish approval for a permanently implanted commercial BCI system.

With roughly $430 million raised, Precision is now firmly among the best-funded private BCI companies. Closing Neuralink's funding gap would still require a financing round larger than Precision's entire cumulative capital to date. That's a big gap, even after a $250 million raise.

Can Synchron compete with Neuralink with much less funding?

Synchron has raised $345 million, far less than Neuralink's $1.33 billion, but its endovascular brain implant follows a different surgical approach that could become an important advantage.

Synchron announced a $200 million Series D in November 2025, led by Double Point Ventures, with participation from ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, Qatar Investment Authority and other investors.

That round represented approximately 58% of all the money Synchron had raised. Together with its $75 million Series C in December 2022, the two financings accounted for almost 80% of its cumulative capital.

Synchron's Stentrode is implanted through a blood vessel near the brain, allowing neural signals to be recorded without the same type of open-brain surgery used by certain competing interfaces. Its initial application involves helping people with severe paralysis control digital devices.

Neuralink and Synchron consequently face different engineering challenges. Neuralink uses penetrating electrodes and robotic implantation, while Synchron relies on a vascular route that may offer different trade-offs in surgical access and neural signal collection.

Synchron's funding is roughly one-quarter of Neuralink's, yet capital raised alone tells us little about which implantation approach will prove more practical for large numbers of patients.

Are non-invasive neurotech startups raising as much as brain-implant companies?

Non-invasive neurotech startups are now attracting hundreds of millions of dollars, although the biggest cumulative funding totals still tend to belong to invasive interfaces and established neurological treatment devices.

Merge Labs is the clearest recent example. The company raised $252 million in seed funding in January 2026, according to Bloomberg. OpenAI confirmed its participation in the round, which supports research combining biology, devices and artificial intelligence to develop new brain-computer interfaces.

The size of that seed financing was extraordinary. Merge raised more in its first announced round than Cognito Therapeutics had accumulated before its own $105 million Series C.

Cognito has a different approach. Its Spectris platform delivers gamma-frequency light and sound through a wearable device designed for people with Alzheimer's disease. The company reported approximately $233 million in total funding after its March 2026 financing.

BrainCo also appears prominently in funding databases, with approximately $336 million associated with its non-invasive neural sensing and assistive technologies. Its applications include brain-sensing interfaces and intelligent prosthetic devices.

These companies share an interest in interacting with the nervous system without placing penetrating electrodes inside the brain, but their technologies are fundamentally different.

Merge is pursuing an ambitious new interface, Cognito is developing a therapeutic product tied to clinical outcomes, and BrainCo has worked on neural sensing and assistive applications. Their funding totals show substantial investor interest across all three approaches. The harder question is whether any of them can deliver the performance, clinical results or practical utility needed for widespread adoption.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Are medical applications attracting most of the neurotech funding?

Medical neurotechnology currently dominates our funding ranking, with most leading companies developing devices for neurological disorders, paralysis, vision loss or chronic pain.

Neuralink's first clinical applications focus on people with severe paralysis. Synchron targets digital-device control for people with major motor impairments, while Precision Neuroscience develops technology for cortical recording and stimulation.

Science Corporation is working on visual restoration. Insightec treats movement disorders with focused ultrasound, Saluda Medical targets chronic pain, and Cognito Therapeutics is developing a device for Alzheimer's disease.

At least eight of the ten companies in our selected comparison have a clearly defined medical treatment or rehabilitation application at the center of their current strategy. BrainCo also operates in assistive technology, leaving very little of this ranking focused on purely consumer-oriented brain enhancement.

The funding also differs in character. Saluda has an established commercial product and reported revenue, Precision has obtained temporary-use regulatory clearance, and Cognito is pursuing pivotal clinical evidence. Merge Labs, by comparison, is receiving substantial financing for a longer-term brain-interface research program.

Investors are supporting both clinically focused devices and ambitious experimental technologies. But the largest group of well-funded neurotech companies still has a clear medical purpose, and the regulatory and clinical milestones attached to those applications provide concrete ways to evaluate progress.

How much neurotech funding is concentrated in the biggest companies?

The three largest companies in our selected neurotech ranking account for roughly 54% of the group's cumulative reported funding, showing how strongly financing is concentrated at the top.

Using the rounded figures and the lower reported figure for Science Corporation, the ten companies together have raised approximately $5.17 billion. Neuralink accounts for $1.33 billion, Insightec roughly $804 million and Saluda Medical $644 million.

Those three companies represent approximately $2.78 billion combined. Adding Science Corporation and Precision Neuroscience takes the total to nearly $3.70 billion, or approximately 72% of the selected group's funding.

The concentration becomes even more pronounced if we look at the financing rounds behind the totals. Neuralink's $650 million Series E alone represents more capital than the entire cumulative funding of Synchron and Merge Labs combined.

These percentages apply only to our selected companies and include some mixed financing categories. They should therefore be used to compare the scale of funding among major neurotech companies rather than estimate the distribution of capital across the entire industry.

Funding group	Combined funding	Share of selected top 10
Neuralink alone	$1.33B	25.7%
Top 2 companies	$2.13B	41.3%
Top 3 companies	$2.78B	53.7%
Top 4 companies	$3.27B	63.2%
Top 5 companies	$3.70B	71.5%
Top 7 companies	$4.38B	84.7%
Top 10 companies	$5.17B	100%

Are neurotech startups raising bigger funding rounds lately?

Large neurotech financing rounds have continued well beyond Neuralink, with five major brain-interface companies announcing approximately $1.58 billion in combined funding across their latest large rounds.

Neuralink announced $650 million in June 2025, followed by Synchron's $200 million in November 2025. Merge Labs raised $252 million in January 2026, Science Corporation announced $230 million in March, and Precision Neuroscience closed $250 million in September.

Three of these rounds happened in 2026 and totaled $732 million. They also represent different stages of development: Merge Labs raised seed financing, Science Corporation completed a Series C, and Precision Neuroscience closed a Series D.

That combination is unusual. Very early-stage neurotech research is attracting funding amounts comparable to those secured by companies with years of engineering, clinical testing and institutional partnerships behind them.

Medical neurotechnology outside BCIs has also received fresh capital. Cognito Therapeutics raised $105 million in March 2026, bringing its cumulative funding to $233 million as it advanced its Alzheimer's treatment device.

Several neurotech companies have recently secured exceptionally large individual rounds. Whether industry-wide funding is accelerating is a separate question that would require a complete annual dataset covering companies across all financing stages. These selected transactions show the scale of the largest deals, rather than proving that the entire market is growing at the same pace.

Does more funding mean Neuralink is ahead of every neurotech competitor?

Neuralink leads the funding race, but companies such as Saluda Medical, Insightec and Precision Neuroscience have reached clinical or commercial milestones that make a simple technology ranking impossible.

Neuralink's $1.33 billion gives it substantial resources for engineering, manufacturing, clinical trials and the development of future implants. Yet cumulative investment is a financial measure, and we cannot convert it directly into clinical effectiveness.

Saluda Medical provides an especially useful comparison because it generated $90.2 million in annual revenue during its financial year ended June 2026. The company is already selling an approved spinal cord stimulation system to healthcare providers.

Insightec also has marketed neurological treatment technology, while Precision Neuroscience has reported more than 100 patient procedures and received clearance for temporary cortical recording and stimulation.

Neuralink is pursuing more demanding long-term applications, including advanced communication and potentially broader brain-machine interaction. That ambition helps attract funding, but some competitors are further along in selling specific approved medical technologies.

A company developing a broadly applicable neural interface could eventually address a much larger market than a device treating one neurological condition. But Neuralink's fundraising lead does not give it a clinical lead across neurotechnology. Saluda, for example, already has something Neuralink is still working toward: a repeatable commercial business with substantial reported revenue.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Why do neurotech funding websites show different totals?

Neurotech funding databases often disagree because they count different transactions, update records at different times and sometimes combine equity, debt and other financing.

Science Corporation provides a clear example. Cooley reported approximately $490 million in total funding after its March 2026 Series C, while CB Insights lists $520 million. Both sources include the $230 million financing, but their cumulative totals differ by approximately $30 million.

Insightec offers another example. Dealroom reports around $797 million, compared with approximately $811 million from CB Insights. A separate issue is its previously announced $200 million debt financing, which makes it difficult to treat the full reported total as venture capital.

Cala Health also demonstrates why recent updates matter. CB Insights currently lists approximately $307 million, including a $50 million financing associated with Trinity Capital in April 2026. Older funding rankings may show considerably lower figures.

Ownership changes create further problems. Saluda Medical completed an IPO in December 2025, while MindMaze underwent a debt restructuring and asset transaction involving NeuroX in 2025. A historical funding figure does not necessarily describe a currently independent private startup.

For our ranking, we give greater weight to company-confirmed cumulative financing when available and use databases to fill remaining gaps. We also keep funding separate from valuations and acquisition prices. Otherwise, two companies can appear directly comparable even though the reported amounts describe different financial events.

Which neurotech startups could raise the most money next?

Precision Neuroscience, Science Corporation and Merge Labs are among the most interesting candidates for another major neurotech financing, but each company now needs to demonstrate something different.

Precision has already raised $430 million and completed more than 100 patient procedures across 18 institutions. The next important milestone would involve extending its clinical and regulatory progress toward a permanent neural interface that can be used commercially.

Science Corporation has raised approximately $490 million to $520 million and is working toward bringing its PRIMA visual-restoration system to market. Its future financing prospects will depend partly on regulatory decisions, clinical outcomes and the practical commercial rollout of the technology.

Merge Labs faces a more fundamental technical challenge. Its $252 million seed financing gives it substantial research capital, but the company still needs to demonstrate that its proposed non-invasive approach can deliver useful brain-computer communication.

Synchron offers another potential contender. Its $200 million Series D was intended to support commercialization of its Stentrode system and further development of neural interfaces.

Neuralink could also return for more financing as its clinical programs and manufacturing requirements expand. Its previous $650 million round shows the scale of investment it has been able to attract, although that historical transaction provides no reliable estimate of its next round.

The next major neurotech financing could therefore come from a company approaching commercial deployment or one pursuing a much earlier but potentially larger technological opportunity. Merge has already shown how much investors will commit before a technology is clinically established. For Precision, Science and Synchron, the case for another large round will increasingly depend on what they can demonstrate beyond engineering prototypes and early clinical use.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

What are the top neurotech startups by total funding raised today?

Neuralink is currently the clear leader in neurotech funding, with approximately $1.33 billion raised and a substantial advantage over every other company in our selected comparison.

Insightec ranks second at approximately $800 million in historical financing, followed by Saluda Medical at roughly $644 million, although Saluda is now publicly listed and Insightec's reported total includes debt.

Among private brain-interface specialists, Science Corporation has emerged as a major competitor with approximately $490 million to $520 million raised. Precision Neuroscience follows with $430 million, while Synchron has accumulated $345 million.

BrainCo, Cala Health, Merge Labs and Cognito Therapeutics also have reported funding totals above $200 million, showing that substantial investment extends beyond surgically implanted brain-computer interfaces.

One comparison captures the current funding landscape particularly well. Science Corporation, Precision Neuroscience, Synchron and Merge Labs together have raised at least $1.5 billion, exceeding Neuralink's cumulative total. Investors are committing substantial capital to several competing approaches rather than backing a single neural-interface architecture.

Neuralink dominates the individual funding ranking, while the broader neurotechnology market remains divided among several technologies with different levels of clinical and commercial maturity. Science Corporation and Precision Neuroscience are now especially important names in the private BCI funding race, and established medical-device companies such as Insightec and Saluda demonstrate how much capital neurological treatment technologies can attract.

The next meaningful shift will come when one of these heavily funded developers turns its clinical progress into a repeatable, widely adopted product. Until then, Neuralink remains the funding leader, while the competition to build the most successful neurotechnology business is still open.